- Walgreens partners with United Nations Foundation's Shot@Life campaign
- Study: Cough-cold manufacturers' voluntary label change on pediatric products reduced ER admissions
- Walgreens partners with Chicago Public Schools and city health department on Tdap vaccination project
- Cardinal Health invites independent pharmacy owners to ‘discover new horizons’ at RBC 2013
- PhRMA report lists 271 vaccines in development
CAMBRIDGE, Mass. British drug maker Shire is working with Cambridge, Mass.-based Acceleron Pharma to develop treatments for serious muscular disorders, Shire said Thursday.
The drug maker announced that the two companies would investigate ACE-031, a drug in mid-stage clinical trials as a treatment for Duchenne muscular dystrophy, a rare and fatal muscle disorder with no current treatment. The drug belongs to a class known as activin receptor type IIB, or ActRIIB molecules.
The two companies will work together to advance ACE-031 into a global phase-2 and -3 clinical program designed to demonstrate disease modification in patients with DMD.
Under the agreement, Shire will pay Acceleron $45 million upfront, and the latter company will be eligible for milestone payments of up to $453 million for ACE-031 and other molecules. If the drug manages to win regulatory approval, Acceleron will have rights to commercialize it in the United States and Canada, while Shire will have rights in other countries.